Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

被引：0
|
作者：
Becky A. S. Bibby
Niluja Thiruthaneeswaran
Lingjian Yang
Ronnie R. Pereira
Elisabet More
Darragh G. McArt
Paul O’Reilly
Robert G. Bristow
Kaye J. Williams
Ananya Choudhury
Catharine M. L. West
机构：
[1] University of Manchester,Translational Radiobiology Group, Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health
[2] Manchester Academic Health Sciences Centre,Sydney Medical School
[3] The Christie NHS Foundation Trust,Translational Oncogenomics
[4] University of Sydney,Centre for Cancer Research and Cell Biology
[5] CRUK Manchester Institute and CRUK Manchester Centre,School of Pharmacy and Pharmaceutical Sciences
[6] Queen’s University Belfast,undefined
[7] University of Manchester,undefined
来源：
BMC Urology | / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Repurposing of FDA-approved lead drugs as potentiators of uterine contractility in postpartum hemorrhage
    Iwueke, Chisom C.
    Hansen, Christopher J.
    Siricilla, Shajila
    Herington, Jennifer L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : S325 - S325
  • [32] Targeting ion channels for cancer therapy by repurposing the approved drugs
    Kale, Vijay Pralhad
    Amin, Shantu G.
    Pandey, Manoj K.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2015, 1848 (10): : 2747 - 2755
  • [33] Repurposing the FDA-approved raloxifene to potentiate gemcitabine cytotoxicity in pancreatic cancer
    Trinh, Jessica
    Badejo, Adeleke
    Love, Quintin
    True, Heather
    Rao, Deepa
    Malhotra, Ashim
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [34] Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
    Benedict, Ashwini
    Bansal, Neha
    Senina, Svetlana
    Hooper, Idris
    Lundberg, Lindsay
    de la Fuente, Cynthia
    Narayanan, Aarthi
    Gutting, Bradford
    Kehn-Hall, Kylene
    FRONTIERS IN MICROBIOLOGY, 2015, 6
  • [35] Repurposing FDA-approved drugs as HIV-1 integrase inhibitors: an in silico investigation
    Ha, Christopher Heng Xuan
    Lee, Nung Kion
    Rahman, Taufiq
    Hwang, Siaw San
    Yam, Wai Keat
    Chee, Xavier Wezen
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (06): : 2146 - 2159
  • [36] Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
    Jose, Sandra
    Devi, Sreevidya S.
    Sajeev, Anjana
    Girisa, Sosmitha
    Alqahtani, Mohammed S.
    Abbas, Mohamed
    Alshammari, Abdulrahman
    Sethi, Gautam
    Kunnumakkara, Ajaikumar B.
    BIOSCIENCE REPORTS, 2023, 43 (03)
  • [37] Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
    Kandeel, Mahmoud
    Al-Nazawi, Mohammed
    LIFE SCIENCES, 2020, 251
  • [38] Repurposing of FDA approved drugs against uropathogenic Escherichia coli: In silico, in vitro, and in vivo analysis
    Kaur, Harpreet
    Kalia, Manmohit
    Chaudhary, Naveen
    Singh, Vikram
    Yadav, Vivek Kumar
    Modgil, Vinay
    Kant, Vishal
    Mohan, Balvinder
    Bhatia, Alka
    Taneja, Neelam
    MICROBIAL PATHOGENESIS, 2022, 169
  • [39] Discovery of new Glyoxalase I inhibitors by repurposing of FDA-approved drugs: An in silico study
    Hoseyni, Khaled
    Sepehri, Bakhtyar
    Irani, Mehdi
    JOURNAL OF MOLECULAR STRUCTURE, 2024, 1312
  • [40] Mebendazole: A candidate FDA approved drug for repurposing in leukaemia
    Matchett, K. B.
    Grishagin, I. V.
    Kettyle, L. M.
    Gavory, G.
    Harrison, T.
    Mills, K. I.
    Thompson, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 121 - 122
12345